Lipases, liposomes and lipid-prodrugs

被引:55
作者
Arouri, Ahmad [1 ,2 ]
Hansen, Anders Hojgaard [1 ,2 ]
Rasmussen, Thomas Elmelund [1 ,2 ]
Mouritsen, Ole G. [1 ,2 ]
机构
[1] Univ Southern Denmark, MEMPHYS Ctr Biomembrane Phys, 55 Campusvej, DK-5230 Odense M, Denmark
[2] Univ Southern Denmark, NanoCAN Lundbeck Nanomed Res Ctr Canc Stem Cell T, DK-5230 Odense M, Denmark
基金
新加坡国家研究基金会;
关键词
Liposome; Drug delivery; Phospholipase; Interface; Prodrug; PHOSPHOLIPASE A(2) ENZYMES; INTESTINAL LYMPHATIC ABSORPTION; GROUP-II PHOSPHOLIPASE-A2; FATTY-ACIDS; TARGETED DELIVERY; CANCER-THERAPY; SECRETORY PHOSPHOLIPASE-A2; POLY(ETHYLENE GLYCOL); CLINICAL DEVELOPMENT; ANTICANCER PRODRUGS;
D O I
10.1016/j.cocis.2013.06.001
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
Colloidal and interfacial phenomena lie at the core of drug formulation, drug delivery, as well as drug binding and action at diseased sites, e.g., in cancer therapy. We review a class of liposome-based drug-delivery systems whose design and functional properties are intimately controlled by the stability of sub-micron structures, lipid-bilayer interfaces, and interfacially activated enzymes that can be exploited to target and deliver drugs. Moreover these drugs can themselves be special lipid molecules in the form of lipid prodrugs that both form the liposomal carrier as well as the substrate for endogenously upregulated lipases that turn the prodrugs into potent drugs precisely at the diseased site. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:419 / 431
页数:13
相关论文
共 184 条
[1]  
Abe T, 1997, INT J CANCER, V74, P245, DOI 10.1002/(SICI)1097-0215(19970620)74:3<245::AID-IJC2>3.0.CO
[2]  
2-Z
[3]   LIPOSOMES WITH PROLONGED CIRCULATION TIMES - FACTORS AFFECTING UPTAKE BY RETICULOENDOTHELIAL AND OTHER TISSUES [J].
ALLEN, TM ;
HANSEN, C ;
RUTLEDGE, J .
BIOCHIMICA ET BIOPHYSICA ACTA, 1989, 981 (01) :27-35
[4]   Enzyme-triggered nanomedicine: Drug release strategies in cancer therapy (Invited Review) [J].
Andresen, Thomas L. ;
Thompson, David H. ;
Kaasgaard, Thomas .
MOLECULAR MEMBRANE BIOLOGY, 2010, 27 (07) :353-363
[5]   Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase A2 in tumor tissue [J].
Andresen, TL ;
Jensen, SS ;
Madsen, R ;
Jorgensen, K .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (23) :7305-7314
[6]   Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs [J].
Andresen, TL ;
Davidsen, J ;
Begtrup, M ;
Mouritsen, OG ;
Jorgensen, K .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (07) :1694-1703
[7]   Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release [J].
Andresen, TL ;
Jensen, SS ;
Jorgensen, K .
PROGRESS IN LIPID RESEARCH, 2005, 44 (01) :68-97
[8]   ORIGIN OF THE LATENCY PHASE DURING THE ACTION OF PHOSPHOLIPASE-A2 ON UNMODIFIED PHOSPHATIDYLCHOLINE VESICLES [J].
APITZCASTRO, R ;
JAIN, MK ;
DEHAAS, GH .
BIOCHIMICA ET BIOPHYSICA ACTA, 1982, 688 (02) :349-356
[9]   Membrane-perturbing effect of fatty acids and lysolipids [J].
Arouri, Ahmad ;
Mouritsen, Ole G. .
PROGRESS IN LIPID RESEARCH, 2013, 52 (01) :130-140
[10]   Phospholipase A2-susceptible liposomes of anticancer double lipid-prodrugs [J].
Arouri, Ahmad ;
Mouritsen, Ole G. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 45 (04) :408-420